Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Feb 7;6(2):e245581.
doi: 10.1001/jamahealthforum.2024.5581.

Burden of Comorbid Conditions Among Individuals Screened for Lung Cancer

Dejana Braithwaite  1   2   3 , Shama Karanth  1   2 , Christopher G Slatore  4   5   6 , Jae Jeong Yang  1   2 , Martin Tammemagi  7 , Michael K Gould  8 , Gerard A Silvestri  9
Affiliations
Multicenter Study

Burden of Comorbid Conditions Among Individuals Screened for Lung Cancer

Dejana Braithwaite et al. JAMA Health Forum. .

Abstract

Importance: Screening for lung cancer with low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality in trials that included relatively younger, healthier, and predominantly White populations. The comorbidity profiles among patients undergoing lung cancer screening in practice settings are poorly understood.

Objective: To evaluate the comorbidity profiles of patients in the Personalized Lung Cancer Screening (PLuS) cohort as a clinical setting vs the National Lung Screening Trial (NLST) participants in a clinical trial setting.

Design, setting, and participants: This multicenter cohort study was conducted across 3 health care systems in California, Florida, and South Carolina and included patients who underwent LDCT lung cancer screening between 2016 and 2021. Data were analyzed between January 1, 2016, and December 31, 2021.

Exposures: Receipt of the LDCT scan identified through Current Procedural Terminology and Healthcare Common Procedure Coding System codes.

Main outcomes and measures: Detailed comorbidity data, measures of pulmonary function, and study data abstracted from electronic health records and institutional, Surveillance, Epidemiology, and End Results (SEER), and state registries were compared with self-reported comorbid conditions of participants in the LDCT arm of the NLST.

Results: The PLuS cohort (n = 31 795) included 49.0% participants aged 65 years or older vs 26.6% in the NLST cohort (n = 26 723); 23.3% were individuals of racial and ethnic minority groups in the PLuS cohort compared with 8.5% in the NLST. The prevalence of comorbidity was substantially higher in the PLuS cohort than the NLST group, particularly chronic obstructive pulmonary disease (32.7% vs 17.5%), diabetes (24.6% vs 9.7%), and heart disease (15.9% vs 12.9%). Among those in the PLuS cohort, 19.3% had a Charlson Comorbidity Index score of 4 or higher, 18.0% had a frailty index greater than 0.20, 16.9% had a forced expiratory volume in 1 second (FEV-1) lower than 50% of predicted, and almost 5% had an ejection fraction lower than 40%. The prevalence of multimorbidity and frailty was especially high among those in the 75 years or older age group.

Conclusions and relevance: This study found that the PLuS cohort members were older, had greater illness severity, and more racially and ethnically diverse than the NLST participants. Older patients and those with consequential comorbidity likely had different risk-benefit profiles, which may have affected screening outcomes. The high prevalence of multimorbidity, frailty, and impaired cardiopulmonary function in the PLuS cohort suggests that the balance of benefits and harms observed in the NLST group may not translate to the clinical setting.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Gould reported personal fees from UpToDate for coauthorship of topics on lung cancer diagnosis and staging outside the submitted work. Dr Silvestri reported grants from Nucleix, Delfi, and Freenome for screening biomarker work, and personal fees from Biodesix outside the submitted work. No other disclosures were reported.

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820 - DOI - PubMed
    1. Aberle DR, Adams AM, Berg CD, et al. ; National Lung Screening Trial Research Team . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873 - DOI - PMC - PubMed
    1. Carroll NM, Burnett-Hartman AN, Joyce CA, et al. . Real-world clinical implementation of lung cancer screening-evaluating processes to improve screening guidelines-concordance. J Gen Intern Med. 2020;35(4):1143-1152. doi:10.1007/s11606-019-05539-w - DOI - PMC - PubMed
    1. Pinsky PF, Gierada DS, Hocking W, Patz EF Jr, Kramer BS. National lung screening trial findings by age: medicare-eligible versus under-65 population. Ann Intern Med. 2014;161(9):627-633. doi:10.7326/M14-1484 - DOI - PMC - PubMed
    1. Henderson LM, Su IH, Rivera MP, et al. . Prevalence of lung cancer screening in the US, 2022. JAMA Netw Open. 2024;7(3):e243190. doi:10.1001/jamanetworkopen.2024.3190 - DOI - PMC - PubMed

Publication types